Life Sciences and Pharma IP Litigation 2025

CHINA Trends and Developments Contributed by: Binxin Li, Guangzhen Shang and Sally Wang, LeanWill Law Firm

Conclusion As the life sciences and pharmaceuticals indus - try in China continues to evolve, stakeholders must navigate the complex terrain of IP litigation. Legislative vigilance, regulatory compliance and strategic enforcement strategies will be pivotal in safeguarding IP in this dynamic and promis - ing sector.

80

CHAMBERS.COM

Powered by